FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 324:1180-1185 April 25, 1991 Number 17 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Cancer treatments without proved efficacy have achieved new levels of popularity, particularly among well-educated patients. The value of these therapies is vigorously debated. METHODS. We compared the length of survival and quality of life in patients who received treatment at a prominent unorthodox cancer clinic in addition to conventional treatment and in matched control patients from an academic cancer center who received only conventional treatment. All the patients had documented extensive malignant disease associated with a predicted median survival time of less than one year. The study sample consisted of 78 pairs of patients matched according to sex, race, age, diagnosis, and time from the diagnosis of metastatic or recurrent disease, who were enrolled over a period of 3 1/2 years. Periodic follow-up (approximately every two months) continued until death. RESULTS. There was no difference between the two patient groups in length of survival. Median survival for both groups was 15 months (P = 0.22; relative risk, 1.23; 95 percent confidence interval, 0.88 to 1.72). Quality-of-life scores were consistently better among conventionally treated patients from enrollment on. CONCLUSIONS. For this sample of patients with extensive disease and for this particular unorthodox treatment regimen, conventional and unorthodox treatments produced similar results.

Source Information

Psychosocial Research Programs, University of Pennsylvania, Philadelphia.

This article has been cited by other articles:

• Cassileth, B. R., Deng, G. E., Gomez, J. E., Johnstone, P. A. S., Kumar, N., Vickers, A. J. (2007). Complementary Therapies and Integrative Oncology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 340S-354S [Abstract] [Full Text]  
• Hlubocky, F. J., Ratain, M. J., Wen, M., Daugherty, C. K. (2007). Complementary and Alternative Medicine Among Advanced Cancer Patients Enrolled on Phase I Trials: A Study of Prognosis, Quality of Life, and Preferences for Decision Making. JCO 25: 548-554 [Abstract] [Full Text]  
• Tascilar, M., de Jong, F. A., Verweij, J., Mathijssen, R. H. J. (2006). Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence. The Oncologist 11: 732-741 [Abstract] [Full Text]  
• Vickers, A. (2004). Alternative Cancer Cures: "Unproven" or "Disproven"?. CA Cancer J Clin 54: 110-118 [Abstract] [Full Text]  
• Correa-Velez, I., Clavarino, A., Barnett, A. G, Eastwood, H. (2003). Use of complementary and alternative medicine and quality of life: changes at the end of life. Palliat Med 17: 695-703 [Abstract]  
• Brown, J. K., Byers, T., Doyle, C., Courneya, K. S., Demark-Wahnefried, W., Kushi, L. H., McTiernan, A., Rock, C. L., Aziz, N., Bloch, A. S., Eldridge, B., Hamilton, K., Katzin, C., Koonce, A., Main, J., Mobley, C., Morra, M. E., Pierce, M. S., Sawyer, K. A. (2003). Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices. CA Cancer J Clin 53: 268-291 [Abstract] [Full Text]  
• Antman, K., Benson, M. C., Chabot, J., Cobrinik, D., Grann, V. R., Jacobson, J. S., Joe, A. K., Katz, A. E., Kelly, K., Neugut, A. I., Russo, D., Tiersten, A., Weinstein, I. B. (2001). Complementary and Alternative Medicine: The Role of the Cancer Center. JCO 19: 55s-60 [Full Text]  
• Paltiel, O., Avitzour, M., Peretz, T., Cherny, N., Kaduri, L., Pfeffer, R. M., Wagner, N., Soskolne, V. (2001). Determinants of the Use of Complementary Therapies by Patients With Cancer. JCO 19: 2439-2448 [Abstract] [Full Text]  
• Berkman, C. S., Pignotti, M. G., Cavallo, P. F., Holland, N. J. (1999). Use of Alternative Treatments by People with Multiple Sclerosis. Neurorehabil Neural Repair 13: 243-254 [Abstract]  
• Cassileth, B. R. (1999). Complementary and Alternative Cancer Medicine. JCO 17: 44-52 [Full Text]  
• Verhoef, M. J., Hagen, N., Pelletier, G., Forsyth, P. (1999). Alternative therapy use in neurologic diseases: Use in brain tumor patients. Neurology 52: 617-617 [Abstract] [Full Text]  
• Sugarman, J., Burk, L. (1998). Physicians' Ethical Obligations Regarding Alternative Medicine. JAMA 280: 1623-1625 [Full Text]  
• Friedman, T., Slayton, W. B., Allen, L. S., Pollock, B. H., Dumont-Driscoll, M., Mehta, P., Graham-Pole, J. (1997). Use of Alternative Therapies for Children With Cancer. Pediatrics 100: e1-e1 [Abstract] [Full Text]